Menu Search
Equities

Grace Therapeutics, Inc

GRCE:NAQ

Grace Therapeutics, Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.05
  • Today's Change-0.14 / -4.39%
  • Shares traded29.90k
  • 1 Year change+41.86%
  • Beta1.4898
Data delayed at least 15 minutes, as of Nov 13 2024 20:57 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in CAD

The 2 analysts offering 12 month price targets for Grace Therapeutics, Inc have a median target of 10.21, with a high estimate of 12.45 and a low estimate of 7.97. The median estimate represents a 234.73% increase from the last price of 3.05.
High308.1%12.45
Med234.7%10.21
Low161.2%7.97

Earnings history & estimates in CAD

On Nov 13, 2024, Grace Therapeutics, Inc reported 2nd quarter 2025 losses of -0.33 per share. This result exceeded the -0.64 consensus loss of the one analyst covering the company and under-performed last year's 2nd quarter results by 23.13%.
The next earnings announcement is expected on Feb 10, 2025.
Average growth rate-16.63%
Grace Therapeutics, Inc reported annual 2024 losses of -0.90 per share on Jun 21, 2024.
Average growth rate+12.64%
More ▼

Revenue history & estimates in CAD

Grace Therapeutics, Inc did not report revenues for the 2nd quarter 2025. However, during the 2nd quarter of the prior year the company reported revenues of 0.00.
Average growth rate0.00%
Grace Therapeutics, Inc did not report revenues for the full year 2024. However, during the prior year the company reported revenues of 0.00.
Average growth rate0.00%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.